Prostate Cancer Clinical Trial

PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer

Summary

Patients with metastatic prostate cancer can undergo MRI-guided prostate Stereotactic body radiation therapy (SBRT) without significant adverse events, similar to what has been reported for patients with localized prostate cancer. We hypothesize that prostate SBRT will be well-tolerated in metastatic prostate cancer patients, with quality of life outcomes similar to what has been reported in non-metastatic prostate cancer patients.

View Full Description

Full Description

The MRidian ViewRay offers delivery of prostate SBRT with real-time MR guidance, which provides superior soft-tissue differentiation with excellent visualization of the prostate. This ViewRay platform offers the ideal setting for this study, that aims at precisely delivering prostate SBRT with a simultaneous integrated boost (when indicated) to visible nodules.

In this study, we hope to demonstrate the safety and feasibility of using 36.25 Gy in 5 fractions, plus a simultaneous integrated boost (when indicated), in patients with metastatic prostate cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Biopsy-proven diagnosis of prostate adenocarcinoma
Age ≥ 18
Must have biopsy-proven metastatic prostate cancer

Exclusion Criteria:

History of prior pelvic radiation (external beam or brachytherapy)
Inability to undergo MRI
AUA score >20
For patients on systemic therapy, enrollment must be within six months of start of therapy unless exception is made by protocol PIs.

Study is for people with:

Prostate Cancer

Estimated Enrollment:

22

Study ID:

NCT04220983

Recruitment Status:

Completed

Sponsor:

Weill Medical College of Cornell University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Weill Cornell Medicine
New York New York, 10065, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

22

Study ID:

NCT04220983

Recruitment Status:

Completed

Sponsor:


Weill Medical College of Cornell University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.